TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00751647

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Treatment
Study: NCT03585439

Intervention type: PROCEDURE
Intervention: Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion
Description: First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
Study: NCT03287804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO2
Description: AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells
Study: NCT01873001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl
Description: 15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg tablets administered by mouth on Day 8
Study: NCT03698474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium picosulfate / Magnesium citrate
Description: bowel preparation formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium picosulfate / Magnesium citrate
Description: bowel preparation formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol / Ascorbic acid
Description: bowel preparation formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol / Ascorbic acid
Description: bowel preparation formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium/ Kalium/ Magnesium sulfate
Description: bowel preparation formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrium/ Kalium/ Magnesium sulfate
Description: bowel preparation formula
Study: NCT06067542

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of impacted mandibular wisdom teeth
Description: All surgical procedures were performed by the same surgeon using the standard surgical technique described below. The anesthetic used was 4% articaine with 1:100,000 adrenaline. In all patients, a sulcus incision was made in the lower second molar and an envelope incision in the third molar region, the mucoperiosteal flap was removed, and extraction was performed with a bone elevator and a third molar elevator. If necessary, the impacted molar was incised with a high-speed dental handpiece and a fissure bur. The wound was irrigated with copious amounts of saline, and the wound edges were carefully sutured with simple 4.0 silk braided non-absorbable sutures.
Study: NCT02204787

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study: NCT05153031

Intervention type: OTHER
Intervention: lithiasic
Description: Cholelithiasis is the presence of one or more calculi (gallstones) in the gallbladder.

Intervention type: PROCEDURE
Intervention: Emergency surgery
Description: Emergency cholecystectomy

Intervention type: PROCEDURE
Intervention: cholecystectomy
Description: cholecystectomy
Study: NCT04065516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARAT technique
Description: After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
Study: NCT02603380

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. No intervention will be given.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study. No intervention will be given.
Study: NCT02599740

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural fruit extract
Description: Natural fruit extract consumed with rice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assumed active
Description: Assumed key active consumed with rice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice only
Study: NCT02283229

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newborns with preventive caring advices
Description: Advices to prevent head molding

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Newborns with normal caring advices
Description: Normal handling
Study: NCT03671434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research-to-Policy Collaboration
Description: The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research-to-Policy Collaboration
Description: The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Touch Policy Training
Description: Control Researchers are provided information on policy engagement via email.
Study: NCT03359954

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo breast surgery
Study: NCT02237703

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
Study: NCT01045330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a modified NTU-HELP
Description: The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
Study: NCT04264676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral Tablet
Description: Supplement of metronidazole 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Supplement of placebo oral tablet 0.4g three times per day for 7 days before each two cycles of chemotherapy (mFOLFOX6 once every 4 weeks, CapeOX once every 6 weeks), which is 6 treatments for mFOLFOX6 and 4 treatments for CapeOX totally.
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
Study: NCT01338506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent Treatment with Prolonged Exposure (COPE)
Description: 12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent Treatment with Prolonged Exposure (COPE)
Description: 12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
Study: NCT00529204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
Study: NCT03353961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation individual therapy
Description: The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual as provided in the community.
Study: NCT02460406

Intervention type: OTHER
Group type: OTHER
Intervention: traditional physiotherapy
Description: We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching \& walking so on).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progressive functional strength training
Description: Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball \& heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly.
Study: NCT02647385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Block with lidocaine for SAM and PEC I block
Description: Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Block with lidocaine for SAM and PEC I block
Description: Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption.
Study: NCT01474993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane-rich Broccoli Sprout Extract
Description: 30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing \~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to \~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~1. Subjects with body weight less than 101 lbs will receive \~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~2. Subjects with body weight 101 lbs to 199 lbs will receive \~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~3. Subjects with bidy weight \> 199 lbs will receive \~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
Study: NCT01924793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F02 Dry Powder in Bulk
Description: Administered via DPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F02 Nebulized Formulation Inhaled Dose
Description: Administered via Nebulizer
Study: NCT01334008

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: 30ml of patient peripherical blood will be collected
Study: NCT00650689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Atorvastatin
Description: oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
Study: NCT01060410

Intervention type: GENETIC
Intervention: Polymorphism Analysis
Description: Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: intravenous injection, 0.2g, once every two days

Intervention type: OTHER
Intervention: Pharmacokinetic analysis
Description: laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
Study: NCT01558791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TBI handout
Description: The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
Study: NCT01172340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and support intervention
Description: Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-listed control group
Description: Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
Study: NCT03702166

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Processing Therapy (CPT)
Description: CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions. CPT is delivered in three phases: education, processing, and challenging.
Study: NCT03952676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moving cupping
Description: 1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Moving cupping placebo
Description: Using of special perforated cups, the manipulation method is the same as the intervention group.
Study: NCT04383691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7. Flexible dosing of study drug will be permitted beginning on Day 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered orally, once daily, in the evening. Subjects will be treated with Placebo.
Study: NCT02517606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy plus HPCS
Description: Conventional physical therapy plus the addition of hip posterolateral complex strengthening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
Study: NCT02807376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon's 'standard of care' stapler
Study: NCT00829374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 5 mg orally three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: 20 mg orally three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo orally three times daily
Study: NCT02851498

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Food product: high-protein pasta and cereal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food product: high-protein pasta and cereal
Study: NCT04008992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BMS-986259
Study: NCT04260542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting/refeeding
Description: 2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting/refeeding
Description: 2-days fasting followed by 2-days of refeeding. During the fasting period the subjects will be hospitalized to control their state of health and ensure fasting compliance. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet/ fasting
Description: 1 month of fasting-mimicking ketogenic diet and subsequent 2-days of refeeding. The subjects will be instructed by nutritional specialist to follow isocaloric ketogenic diet consisting of 6% carbohydrates, 17 % of proteins and 77% fat to cover individual energy demand. During refeeding the standardized meals will be provided to cover individual daily requirements (60% carbohydrates, 15% protein, 25 % fat).
Study: NCT01794806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and grafting with allograft
Description: Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Tooth extraction
Description: Minimally traumatic single-rooted tooth extraction
Study: NCT02807376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethicon Powered Vascular Stapler
Study: NCT05836428

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04123847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing and Stepping
Description: Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation
Description: Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
Study: NCT02630459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: erenumab via subcutaneous injection